Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus

Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling intravenous dosing in patients with metastatic canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Illingworth, Sam, Di, Ying, Bauzon, Maxine, Lei, Janet, Duffy, Margaret R., Alvis, Simon, Champion, Brian, Lieber, André, Hermiston, Terry, Seymour, Len W., Beadle, John, Fisher, Kerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415321/
https://www.ncbi.nlm.nih.gov/pubmed/28480328
http://dx.doi.org/10.1016/j.omto.2017.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415321/
https://www.ncbi.nlm.nih.gov/pubmed/28480328
http://dx.doi.org/10.1016/j.omto.2017.03.003

Ejemplares similares